Sionna Therapeutics, Inc.’s SION share price has surged by 5.43%, which has investors questioning if this is right time to ...

Oregon Health & Science University, in collaboration with Oregon State University, has discovered the structural organization ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

DelveInsight's " Aplastic Anemia Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

That study showed the competitive inhibitory profile of chlortetracycline and the catalytic binding domain of EphB1 tyrosine kinase (transmembrane proteins that mediate communication between cells).